Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Regeneron Pharmaceuticals is conducting a clinical study titled A Phase 2, Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Subcutaneously Administered REGN7999 (an Inhibitor of TMPRSS6) in Participants with Iron Overload Due to Non-Transfusion Dependent β-Thalassemia. The study aims to assess the safety and effectiveness of REGN7999 in reducing iron overload in patients with non-transfusion dependent beta-thalassemia, using MRI scans to measure iron levels.
The intervention being tested is REGN7999, an experimental antibody administered subcutaneously. It is designed to inhibit TMPRSS6, potentially reducing iron overload in affected patients.
The study follows a randomized, parallel intervention model with a quadruple masking approach, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose is treatment-focused.
The study began on May 14, 2024, with its last update submitted on August 27, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
This study could significantly impact Regeneron’s market position, potentially boosting investor confidence if successful. It also positions Regeneron competitively within the pharmaceutical industry, particularly in the niche market of beta-thalassemia treatments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.